COMPANY BACKGROUND

Dr.Reddy’s Laboratories Ltd founded in 1984 by Dr k.Angi Reddy has become India’s second biggest pharmaceutical company and its headquartered is in Hyderabad.

It produces and sells active pharmaceutical ingredients , finished dosages and biologics.

It manufactures ulcer medicines, antibiotics, pain relievers, antidepressants and cardiovascular drugs.

COMPANY BACKGROUND

Dr Reddy’s market its product in approximately 100 countries , focusing on Europe,India,US and Russia.

The company employed over 8255 personnel,

In 1997 it became the first Indian company to out-license an original molecule (DRF 2593).

Its revenue for 2006 - 2007 amounted to $ 1.5 billion, an increase of 24.3% of the previous year . Its net income amounts to $ 216 million.

COMPANY BACKGROUND

ON 11 April 2001, Dr Reddy’s became the first pharmaceutical company from Asia Pacific to be listed on Newyork stock exchange.

The company carries out research and development in diabetes, cancer, cardiovascular diseases and bacterial infections.

The company has over 120 medications and 60 active pharmaceutical ingredients for drug manufacture.

Key personnel

Chairman: Dr. K.Angi Reddy

CEO: G V Prasad

Dr Reddy’s laboratories in European union

In 2006 – 2007, Dr Reddy’s generated a revenue of EUR 80.5 million from Europe , which accounted for 18% of the company’s total revenue.

Dr Reddy’s Laboratories in Germany

In march 2006 Dr.reddy’s acquired Betapharm arzneimittel GmbH from 3i for euro 480 million. Betapharm employs more than 350 personnel and its turnover amounts to Euro 186 million . It commands a share of 3.5 % in the German pharmaceutical market.

Dr.Reddy Laboratory in UK

In March 2002 Dr Reddy’s acquired BHM Laboratories ,Beverley, and its wholly owned subsidiary meridian health care, EURO 14.81 million. Recently Dr. Reddy’s entered into R & D and Commercialization agreement with Argenta Discovery Ltd, for the treatment of COPD

In other European countries

Apart from subsidiaries in Germany and UK , Dr.Reddy’s has agreements in following European countries.

DENMARK IRELAND NETHERLANDS

Factors for success

Controlling the entire value chain Implementations of efficient new

product development processes High standard of corporate governance

Controlling the entire value chain

Dr.Reddy’s controls the entire supply chain and offers high quality products at competitive prices at opportune time . In addition it ensures that quality is maintained at every stage.

Implementations of efficient new product development processes Targeting the streamlining of new product development process, Dr. Reddy’s implemented project ‘racha’ using Microsoft accelerator for six sigma. This is helping the company in taking key decisions to launch the right products in the market at the appropriate time.

High standard of corporate governance

Dr.Reddy’s adherence to high standard of corporate governance and ethical business practices has been a key factor to its success. The mutual trust has ensured greater success for the company.

Future plans

Having acquired Betapharm, one of the fastest growing generic companies in Germany over the past 5 years, Dr.Reddy’s aims at leveraging this strategic investment to evolve into a mid-sized global pharmaceutical company. Dr.Reddy’s aims to increase its revenue substantially and improve its operating margin.